搜索
Processa Pharmaceuticals Inc
PCSA添加自选
2.960USD
-0.110-3.58%
收盘 05/15, 16:00（美东）报价延迟15分钟
7.93M总市值
亏损市盈率 TTM
查看详细走势图
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-3.58%
5天
+8.42%
1月
-6.92%
6月
-60.53%
今年开始到现在
+2.78%
1年
+1161.18%
TradingKey Processa Pharmaceuticals Inc股票评分
单位: USD 更新时间: 2026-05-15操作建议
Processa Pharmaceuticals Inc当前公司基本面数据相对非常健康，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名146/382位。机构持股占比非常高，近一月多位分析师给出公司评级为。最高目标价25.00。中期看，股价处于上升通道。近一个月，市场表现较强，基本面评分较高，但较强的走势得没有得到技术面的印证。目前股价在压力位和支撑位之间，可以做区间波段操作。
Processa Pharmaceuticals Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
看空
Processa Pharmaceuticals Inc亮点
亮点风险
Processa Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of Next Generation Cancer therapy (NGC) small molecules. The three NGC treatments in its pipeline are NGC-Capecitabine (NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem) and PCS11T, also referred to as NGC-Irinotecan (NGC-Iri) and two non-oncology drug assets are PCS12852, and PCS499. NGC-Cap is a combination of PCS6422 and capecitabine, capecitabine being the oral prodrug of the cancer drug 5-fluorouracil.PCS3117 is an oral analog of gemcitabine that is converted to its active metabolite by a different enzyme system than gemcitabine. PCS11T is a prodrug of the active metabolite of irinotecan (SN-38). PCS12852 is a specific and potent 5HT4 agonist that is in Phase IIB and is a potential treatment for diabetic gastroparesis patients. PCS499 is a drug that can be used to treat unmet medical needs and conditions caused by multiple pathophysiological changes.
利润高增长
公司净利润处于行业前列，最新年度总收入0.00美元
估值低估
公司最新PE估值-0.70，处于3年历史低位
机构加仓
最新机构持股128.65K股，环比增加22.02%
先锋集团持仓
明星投资者先锋集团持仓，最新持仓市值0.00
分析师目标
根据
0
位分析师
--
评级
25.000
目标均价
+714.33%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Processa Pharmaceuticals Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Processa Pharmaceuticals Inc简介
Processa Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of Next Generation Cancer therapy (NGC) small molecules. The three NGC treatments in its pipeline are NGC-Capecitabine (NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem) and PCS11T, also referred to as NGC-Irinotecan (NGC-Iri) and two non-oncology drug assets are PCS12852, and PCS499. NGC-Cap is a combination of PCS6422 and capecitabine, capecitabine being the oral prodrug of the cancer drug 5-fluorouracil.PCS3117 is an oral analog of gemcitabine that is converted to its active metabolite by a different enzyme system than gemcitabine. PCS11T is a prodrug of the active metabolite of irinotecan (SN-38). PCS12852 is a specific and potent 5HT4 agonist that is in Phase IIB and is a potential treatment for diabetic gastroparesis patients. PCS499 is a drug that can be used to treat unmet medical needs and conditions caused by multiple pathophysiological changes.
公司代码PCSA
公司Processa Pharmaceuticals Inc
CEONg (George K)
网址https://www.processapharmaceuticals.com/
相关品种
